GPRC5D Targeting Drugs Market Opportunity and Clinical Trials Insight 2024: Insight on 15+ Drugs in Clinical Trials
June 07, 2024 03:32 ET
|
Research and Markets
Dublin, June 07, 2024 (GLOBE NEWSWIRE) -- The "Global GPRC5D Targeting Drugs Market Opportunity and Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering. In...
FDA Grants Orphan Drug Designation to Biompharma’s Bi104, a microbiome-modifying biologic, for the treatment of Angelman Syndrome
May 08, 2024 09:25 ET
|
Biom Pharmaceutical Corporation
Sarasota, Florida, May 08, 2024 (GLOBE NEWSWIRE) -- BIOM Pharmaceutical Corporation is thrilled to announce that Bi104, its innovative drug product, has been granted orphan-drug designation by the...
Global CD70 Targeting Therapies Market & Clinical Trials Report 2024 - Insight by Company, Country, Indication & Phase
April 29, 2024 07:32 ET
|
Research and Markets
Dublin, April 29, 2024 (GLOBE NEWSWIRE) -- The "Global CD70 Targeting Therapies Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering. ...
Global PLK Targeted Therapies Market Opportunity & Clinical Trials Insight 2024 - Groundbreaking Advances in PLK Targeted Therapies Promise to Revolutionize Treatment for Cancer and Other Diseases
April 29, 2024 06:53 ET
|
Research and Markets
Dublin, April 29, 2024 (GLOBE NEWSWIRE) -- The "Global PLK Targeted Therapies Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's...
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
April 16, 2024 08:00 ET
|
PharmaTher Holdings Ltd.
TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, provides an update of its...
Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals
April 08, 2024 08:30 ET
|
Longeveron
CEO Letter to Shareholders. Update on overall strategy, business objectives, approach to capital allocation, and 2024 key priorities and goals.
Intelligencia AI Awarded U.S. Patent for Its Accurate and Transparent Probability of Drug Success Assessments
April 02, 2024 13:43 ET
|
Intelligencia AI
Health tech company pioneers de-risking clinical development through patented algorithms, technology and use of artificial intelligence
Intelligencia AI Ranks No. 90 on Inc. Magazine’s List of the Northeast Region’s Fastest-Growing Private Companies
March 20, 2024 09:18 ET
|
Intelligencia AI
Inc. magazine recently revealed that Intelligencia AI, a provider of AI-powered decision-making solutions for the pharmaceutical industry, ranks No. 90.
Global Bispecific Antibody Market, Drugs Sales, Patent, Price & Clinical Trials Insight 2029: 800+ Bispecific Candidates Currently in Active Clinical Development
March 18, 2024 05:16 ET
|
Research and Markets
Dublin, March 18, 2024 (GLOBE NEWSWIRE) -- The "Global Bispecific Antibody Market, Drugs Sales, Patent, Price & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's...
Global Contract Research Organization Services Market Analysis & Forecast to 2023-2033: Pharmaceutical Giants Ramp Up Investments Amidst Rising Chronic Disease Burden
March 13, 2024 12:01 ET
|
Research and Markets
Dublin, March 13, 2024 (GLOBE NEWSWIRE) -- The "Global Contract Research Organization Services Market Analysis & Forecast to 2023-2033: Market By Service; By Application; By End-user; and By...